Lilly(Eli) & Co


Market Cap$768.36B

Compare Lilly(Eli) &

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Lilly(Eli) & CoLilly(Eli) & Co125.20.6%48%21.82
marketMarket Avg53.91.27%26%-1.2
HealthcareHealthcare Avg30.31.33%16%7.51.3

Earnings Call Q4 2023

February 6, 2024 - AI Summary

Revenue in Q4 2023 grew by 28% compared to the same period in 2022, driven by new product launches and growth products.
Key pipeline milestones were achieved, including positive Phase III results for Tirzepatide and Verzenio, as well as positive Phase II results for Orforglipron and Retatrutide.
Several acquisitions and collaborations were completed to enhance the pipeline, including the acquisition of POINT Biopharma and the entry into radioligand therapy.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

6.4% upsideLilly(Eli) & Target Price DetailsTarget Price

Current Fair Value

66.3% downside

Overvalued by 66.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$768.36 Billion
Enterprise Value$791.98 Billion
Dividend Yield$4.8479 (0.6%)
Earnings per Share$6.79
Outstanding Shares950,405,386
Avg 30 Day Volume2,880,730


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio125.17
Price to Sales21.82
Price to Book Ratio62.11
Enterprise Value to Revenue22.04
Enterprise Value to EBIT69.8
Enterprise Value to Net Income129
Total Debt to Enterprise0.03
Debt to Equity2.05

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Lilly(Eli) & Co

CEO: David Ricks